LFG
KYMR icon

Larson Financial Group’s Kymera Therapeutics KYMR Stock Holding History

Larson Financial Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Sell
955
-6
-0.6% -$516 ﹤0.01% 1137
2026
Q1 		$80K Sell
961
-103
-10% -$8.16K ﹤0.01% 1099
2025
Q4 		$82.8K Buy
1,064
+287
+37% +$19.4K ﹤0.01% 998
2025
Q3 		$44K Buy
777
+349
+82% +$15.7K ﹤0.01% 1215
2025
Q2 		$18.7K Buy
+428
New +$14.7K ﹤0.01% 1521

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Larson Financial Group's KYMR Position: Q2 2026 in Review

Larson Financial Group reduced its Kymera Therapeutics (KYMR) stake by 0.62% in Q2 2026, selling an estimated $516 and leaving 955 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Larson Financial Group first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Larson Financial Group held 955 shares of Kymera Therapeutics worth $110K as of Q2 2026.
  • Larson Financial Group sold 6 Kymera Therapeutics shares in Q2 2026, an estimated $516.
  • Kymera Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1137 holding.
  • Larson Financial Group first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.